Following a limited submission
AWMSG advice |
||||
| Status: Recommended | ||||
Abiraterone is recommended for use within NHS Wales with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Abiraterone should be prescribed on the basis of lowest acquisition cost. |
||||
|
||||
Medicine details |
||||
| Medicine name | abiraterone | |||
| Formulation | 250 mg and 500 mg tablet | |||
| Reference number | 6441 | |||
| Indication | With prednisolone for the treatment of newly-diagnosed high-risk, metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)Abiraterone is recommended for use within NHS Wales with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). |
|||
| BNF chapter | Malignant disease & immunosuppression | |||
| Assessment type | Limited | |||
| Status | Recommended | |||
| Scrutiny Panel meeting date | 09/01/2025 | |||
| LOWMAG meeting date | 07/04/2025 | |||
| AWMSG meeting date | 20/05/2025 | |||
| Date of issue | 29/05/2025 | |||
| Further information This recommendation is interim to the review of NICE Technology Appraisal 721. |
||||